The FY2025 (Dec) proxy of Innoviva names 17 peer companies for pay. Among Innoviva and these peers, CEO pay was 3rd highest of 4 and total shareholder return was 2nd highest of 4.
3rd highest of 4in Innoviva and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$27.8M
2nd highest of 4in Innoviva and its pay peers, FY2025 (Dec) by total shareholder return:
$63$414
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| Travere Therapeutics | ||
| Agios Pharmaceuticals | ||
| Amarin Corporation plc | Not disclosed | Not disclosed |
| Arvinas, Inc. | Not disclosed | Not disclosed |
| Catalyst Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Coherus BioSciences, Inc. | Not disclosed | Not disclosed |
| DRI Healthcare Trust | Not disclosed | Not disclosed |
| Ligand Pharmaceuticals | Not disclosed | Not disclosed |
| MacroGenics, Inc. | Not disclosed | Not disclosed |
| Morphic Holding, Inc. | Not disclosed | Not disclosed |
| Savara Inc. | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Theravance Biopharma, Inc. | Not disclosed | Not disclosed |
| Verona Pharma plc | Not disclosed | Not disclosed |
| Xencor, Inc. | Not disclosed | Not disclosed |
| Xeris Biopharma Holdings | Not disclosed | Not disclosed |
17 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.